Skip to main content

Table 1 Double-blind, randomized, placebo-controlled crossover studies of treatment of children with fragile X syndrome a

From: A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial

Clinical trial registration number Type Compound Population Target Status Promoter Results (reported or pending)
NCT01894958 Phase II multicentre NNZ-2566 Adolescent and adult males NMDA antagonists Recruiting Neuren Pharmaceuticals (USA) Pending
NCT01725152 Phase II single centre Ganaxolone Adolescents and children GABA-A agonist Recruiting Marinus Pharmaceuticals (USA) Pending
NCT02126995 Phase II single centre Metadoxine (MG01CI) Adults and adolescents Ion pair of pyridoxine (vitamin 6) Not yet recruiting Alcobra Pharma (USA) Pending
NCT01474746 Phase II single centre Sertraline Children Selective serotonin reuptake inhibitors Recruiting University of California, Davis (USA) Pending
NCT01911455 Phase II and III Multicentre Acamprosate Adolescents and children NMDA receptor modulators Recruiting Children’s Hospital Medical Center (Cincinnati, OH, USA) Pending
NCT01357239 Phase II multicentre Mavoglurant (AFQ056) Adolescents and adults mGlur5 antagonist Terminated Novartis (Basel, Switzerland) [62]
NCT01013480 Phase II multicentre Arbaclofen (STX209) Adolescents and adults GABA-B agonist Terminated Seaside Therapeutics (USA) [63]
NCT01053156 Phase II single centre Minocycline Adolescents and children Antibiotic Completed University of California, Davis (USA) [65]
NCT01015430 Phase II multicentre Basimglurant (RO4917523) Adults mGlur5 antagonist Completed Hoffmann-La Roche Pending
NCT00895752 Phase IV single centre Riluzole Adults Inhibitor of glutamate release Completed Indiana University (USA) [66]
NCT01254045 Phase II single centre Oxytocin Adolescents and adults Social brain neuropeptides Completed Stanford University (USA) [67]
NCT01120626 Open label Donepezil Adolescents and children Cholinergic drug Completed Stanford University (USA) [68]
  1. aGABA, γ-aminobutyric acid; GABA-B, γ-aminobutyric acid; mGluR5, metabotropic glutamate receptor 5; NMDA, N-methyl-D-aspartate.